September 16, 2019Circulation

Dapagliflozin did not significantly change mean NT-proBNP (p=0.43) but increased the proportion of patients with a ≥5-point improvement in KCCQ or ≥20% reduction in NT-proBNP (61.5% vs 50.4%, adjusted OR 1.8, 95% CI 1.03-3.06, p=0.039).

View Full Paper

Ask AI

Bookmark

Why the study?

The effects of sodium-glucose co-transporter-2 inhibitors in patients with established heart failure with reduced ejection fraction, including those with and without type 2 diabetes mellitus, remained unknown.

Does dapagliflozin 10 mg daily improve NT-proBNP or Kansas City Cardiomyopathy Questionnaire scores in patients with heart failure with reduced ejection fraction?

Population

263 HF patients with LVEF ≤40%, NYHA class II-III, eGFR ≥30 mL/min/1.73m 2, and elevated natriuretic peptides

Comparison

Dapagliflozin 10 mg daily vs placebo

Design

Investigator-initiated, multi-center, randomized controlled trial

Follow-up

12 weeks

Authors

MNMichael E. Nassif SWSheryl L. Windsor FTFengming Tang

Discussion

Member takes

Overview

Do not expect mean NT-proBNP change; extends SGLT2i evidence to health-status responders in HFrEF, with or without diabetes.

Structured PICO

Does dapagliflozin 10 mg daily improve NT-proBNP or Kansas City Cardiomyopathy Questionnaire scores in patients with heart failure with reduced ejection fraction?

Population

263 patients with heart failure with reduced ejection fraction (LVEF ≤40%), NYHA class II-III, estimated glomerular filtration rate ≥30 mL/min/1.73m2, and elevated natriuretic peptides

Intervention

Dapagliflozin 10 mg daily for 12 weeks

Comparator

Placebo for 12 weeks

Outcome

Dual primary outcomes: (1) mean NT-proBNP and (2) proportion of patients with ≥5-point increase in heart failure disease-specific health status on the Kansas City Cardiomyopathy Questionnaire overall summary score, or a ≥20% decrease in NT-proBNP at 12 weekscomposite

In patients with HFrEF, dapagliflozin over 12 weeks increased the proportion of patients experiencing clinically meaningful improvements in HF-related health status or natriuretic peptides, regardless of type 2 diabetes status.

Cite This Study

Nassif et al. (2019) studied this question.

synapsesocial.com/papers/6a7f5aff9cb08e5f0c2ff638 https://doi.org/10.1161/circulationaha.119.042929

View Full Paper

Ask AI

Bookmark

September 16, 2019Circulation

Dapagliflozin did not significantly change mean NT-proBNP (p=0.43) but increased the proportion of patients with a ≥5-point improvement in KCCQ or ≥20% reduction in NT-proBNP (61.5% vs 50.4%, adjusted OR 1.8, 95% CI 1.03-3.06, p=0.039).

View Full Paper

Ask AI

Bookmark

Why the study?

Does dapagliflozin 10 mg daily improve NT-proBNP or Kansas City Cardiomyopathy Questionnaire scores in patients with heart failure with reduced ejection fraction?

Population

263 HF patients with LVEF ≤40%, NYHA class II-III, eGFR ≥30 mL/min/1.73m 2, and elevated natriuretic peptides

Comparison

Dapagliflozin 10 mg daily vs placebo

Design

Investigator-initiated, multi-center, randomized controlled trial

Follow-up

12 weeks

Authors

MNMichael E. Nassif SWSheryl L. Windsor FTFengming Tang

Discussion

Member takes

Overview

Do not expect mean NT-proBNP change; extends SGLT2i evidence to health-status responders in HFrEF, with or without diabetes.

Structured PICO

Does dapagliflozin 10 mg daily improve NT-proBNP or Kansas City Cardiomyopathy Questionnaire scores in patients with heart failure with reduced ejection fraction?

Population

263 patients with heart failure with reduced ejection fraction (LVEF ≤40%), NYHA class II-III, estimated glomerular filtration rate ≥30 mL/min/1.73m2, and elevated natriuretic peptides

Intervention

Dapagliflozin 10 mg daily for 12 weeks

Comparator

Placebo for 12 weeks

Outcome

Cite This Study

Nassif et al. (2019) studied this question.

synapsesocial.com/papers/6a7f5aff9cb08e5f0c2ff638 https://doi.org/10.1161/circulationaha.119.042929

View Full Paper

Ask AI

Bookmark